| Assessment Status | Rapid Review complete |
| HTA ID | 24019 |
| Drug | Artesunate |
| Brand | Artesunate Amivas® |
| Indication | For the initial treatment of severe malaria in adults and children. |
| Assessment Process | |
| Rapid review commissioned | 29/05/2024 |
| Rapid review completed | 26/06/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that IV Artesunate Amivas® not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
